Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting - Episode 4

General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.